Trial Profile
A Study to Evaluate the Survival Outcome Before and After the Approval of Bortezomib in Patients With Multiple Myeloma (MM)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 May 2016
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 19 May 2016 New trial record